Elan Pharmaceuticals, Inc.

Wyeth

Brian P Stupi

Eugene D Thorsett

Andrei William Konradi

Michael A Pleiss

Christopher Michael Semko

Ying-Zi Xu

Jenifer Lea Smith

Frank Stappenbeck

Disclosed are compounds which bind &#x3b1;integrins, preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by &#x3b1;integrins, preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

[object Object]

Disclosed are compounds which bind &#x3b1;integrins, where the &#x3b1;integrin is preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by &#x3b1;integrins, where the &#x3b1;integrin is preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Growing community of inventors

Moss Beach, CA, United States of America

Brian P Stupi